House Panels Press Biogen For Docs, Info On Aduhelm’s Approval, Price

By Beth Wang / July 13, 2021 at 2:12 PM
Two key House committees want Biogen to hand over a slew of documents related to the approval, marketing and pricing of its contentious Alzheimer’s drug Aduhelm (aducanumab), as well as information related to the company’s decision to seek FDA approval of its other investigational Alzheimer’s drug, lecanemab, which recently received Breakthrough Therapy designation from FDA. The documents will assist committee leaders with their investigation into the approval and $56,000 annual price of the drug. House Energy & Commerce Chair Frank...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.